Home / Health / Unprecedented Cancer Treatment Offers New Hope
Unprecedented Cancer Treatment Offers New Hope
31 May
Summary
- A new injection eradicated tumors in 15 patients in an 11-nation trial.
- Tumors shrank in over a third of patients resistant to other treatments.
- The drug amivantamab targets tumor-aiding proteins and cancer resistance pathways.
Doctors are celebrating unprecedented trial results for amivantamab, an injection developed by Johnson & Johnson. This treatment has successfully eliminated tumors in some patients who were resistant to conventional therapies like chemotherapy and immunotherapy.
An 11-nation clinical trial administered amivantamab to patients with advanced or recurring cancer. Tumors shrank in over a third of participants, with complete eradication reported in 15 individuals. This represents a significant breakthrough for patients with limited treatment options.
The trial involved 102 patients with head and neck cancer. Of these, 43 experienced tumor shrinkage or complete disappearance. Amivantamab operates by targeting proteins essential for tumor growth and blocking pathways cancer cells use to resist treatment, while also signaling the immune system to attack tumors.
Patients in the trial lived a median of 12.5 months after treatment initiation, despite their poor prognoses. The drug is also showing promising results in certain lung cancers and is under investigation for colorectal, brain, and gastric cancers in approximately 60 ongoing clinical trials.
